P2X Receptor

P2X7-IN-2 is a potent inhibitor of the P2X7 receptor, demonstrating an IC50 value of 0.01 nM for the inhibition of IL-1β release. This compound is valuable in research focusing on the mechanisms of autoimmunity, inflammation, and cardiovascular disease. Its selective action on the P2X7 receptor makes it a critical tool for studying inflammatory pathways and potential therapeutic interventions.

PSFL2915 is a selective inhibitor of the P2X receptor family, exhibiting an IC50 of 0.319 μM for human P2X3 and 0.261 μM for rat P2X2/3, with approximately 42-fold selectivity for human P2X3 over human P2X2. This compound inhibits human P2X3 activation by disrupting the allosteric tightening of the inner pocket necessary for channel opening, with dependency on magnesium for its inhibitory effect. Additionally, PSFL2915 demonstrates inhibitory activity against rat P2X2/3 and human P2X2 receptors, while showing minimal effects on human P2X1, P2X4, and P2X7 receptors. It is applicable in chronic cough research.

AZD9056 hydrochloride is a selective oral inhibitor of the P2X7 receptor, which is implicated in various inflammatory and pain-related conditions. By blocking P2X7 activity, this compound demonstrates potential in modulating inflammatory responses, making it a valuable tool for research in pain management and inflammatory disease pathways. Its application in preclinical studies may help elucidate the role of purinergic signaling in various biological processes.

NP-1815-PX sodium is a selective inhibitor targeting the P2X4 receptor, exhibiting an IC50 of 0.26 μM against human P2X4 receptors. This compound effectively inhibits ATP-mediated prostaglandin production and attenuates TP receptor-induced calcium elevation, as well as NLRP3 inflammasome signaling. Notably, NP-1815-PX sodium demonstrates anti-allodynic effects in vivo and alleviates DNBS-induced colitis symptoms, including weight loss and tissue damage, through the downregulation of IL-1β levels and Caspase-1 activity. This reagent is applicable in research areas such as asthma and inflammatory bowel disease.

Taspine is a natural product that functionally inhibits the P2X4 receptor, primarily through the inhibition of the PI3K signaling pathway. This compound exhibits notable anti-inflammatory activity by suppressing pro-inflammatory signaling in macrophages. Taspine is valuable for research applications focused on inflammation and immune responses, as well as studying the role of purinergic receptors in various pathological conditions.

P2X3-IN-1 is a selective inhibitor of the P2X3 receptor, which plays a crucial role in mediating pain and other neurogenic responses. This compound demonstrates significant biological activity in modulating P2X3 receptor signaling, making it valuable for research into neurogenic diseases and pain pathways. Researchers can utilize P2X3-IN-1 to explore therapeutic strategies for conditions associated with P2X3 receptor dysfunction.

P2X4 antagonist-1 is a potent inhibitor of the P2X4 receptor, exhibiting an IC50 of 15 nM. This compound effectively modulates P2X4 signaling, making it valuable for research involving pain modulation, neuroinflammation, and cardiovascular regulation. Its specificity towards P2X4 supports studies aimed at understanding its role in various pathophysiological conditions.

Purotoxin 1 is a selective P2X3 receptor inhibitor. It exhibits significant antinociceptive effects in animal models of inflammatory pain, making it a valuable tool for pain research. Isolated from the venom of the wolf spider Geolycosa sp., Purotoxin 1 can be utilized in studies aimed at understanding pain mechanisms and developing new analgesic therapies.

NF864 is a selective inhibitor of the P2X1 receptor, primarily expressed in human platelets. This compound effectively disrupts ATP-mediated signaling cascades involved in platelet activation and aggregation. NF864 is useful in research applications focused on cardiovascular disease, thrombosis, and platelet-related disorders, allowing scientists to investigate the role of P2X1 in vascular biology.

P2X4-IN-1 is a potent inhibitor of the P2X4 receptor, which is involved in various physiological processes including pain perception and inflammation. This compound demonstrates significant biological activity by selectively blocking P2X4 receptor signaling. Its application in research allows for the investigation of therapeutic strategies for diseases associated with P2X4 receptor dysregulation.

GSK1370319A is a selective inhibitor of the human P2X7 receptor, demonstrating an IC50 of 474 nM and a Ki of 176 nM. This compound effectively inhibits the production of interleukin-1 beta (IL-1β), decreases the generation of reactive oxygen species (ROS), and enhances macrophage survival rates. GSK1370319A is applicable in research related to inflammatory bowel disease and the broader study of inflammatory processes.

P2X receptor-1 is a selective inhibitor of P2X receptors, which play a critical role in mediating pain and inflammatory responses. This compound has potential applications in research focused on understanding nociception and addressing inflammatory conditions. Its ability to modulate P2X receptor activity makes it an important tool for exploring therapeutic strategies in pain management and inflammation research.

TC-P 262 is a highly effective inhibitor of the P2X3 receptor, a key player in pain and inflammatory responses. By binding to the human P2X3 receptor, TC-P 262 demonstrates significant inhibitory effects, making it a valuable tool for studying conditions such as rheumatoid arthritis, chronic cough, and pain management. This reagent facilitates the exploration of P2X3's role in these biological processes, contributing to the understanding of potential therapeutic interventions.